Gesynta Pharma AB is raising MSEK 190 in one of the largest private investments in biotech in the Nordic region this year. The funding round is being led by Hadean Ventures, with support from Industrifonden. Gesynta Pharma hired law firm Lindahl to act as an advisor during the investment.
Gesynta Pharma develops drugs to treat patients with systemic sclerosis, a rare autoimmune disease that, among other things, leads to reduced blood flow and increased connective tissue production in the skin and internal organs.
The investment enables Gesynta to fund the continued development of the leading drug candidate GS-248 for treatment of patients with systemic sclerosis. Following a successful phase I study, a multicentre phase IIa study is now being planned involving patients starting in Q4 2020.
Lindahl’s team for Gesynta consists of Michael Edquist, Therese Norenäs, Joakim Gustafsson, Emelie Carmhagen Wernoff and Amanda Sjöberg.